Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer
Authors
Kim Edmunds
Paul Scuffham
Penny Reeves
Daniel A. Galvão, Edith Cowan UniversityFollow
Dennis R. Taaffe, Edith Cowan UniversityFollow
Robert U. Newton, Edith Cowan UniversityFollow
Nigel Spry, Edith Cowan UniversityFollow
David Joseph, Edith Cowan UniversityFollow
Haitham Tuffaha
Author Identifier
Daniel A Galvao
https://orcid.org/0000-0002-8209-2281
Dennis R Taaffe
https://orcid.org/0000-0001-6381-1597
Robert U Newton
Document Type
Journal Article
Publication Title
European Journal of Cancer Care
Volume
30
Issue
5
Publisher
Wiley
School
Exercise Medicine Research Institute / School of Medical and Health Sciences / Centre for Exercise and Sports Science Research
RAS ID
36195
Funders
Edith Cowan University
Griffith University
Abstract
Prostate cancer (PCa) patients with bone metastases tend to have significant functional impairment from long-term androgen deprivation therapy (ADT), exacerbated by subsequent treatments such as second-line hormone therapies (abiraterone and enzalutamide), first- and second-line chemotherapy or immunotherapies (Hart et al., 2017). They are at significant risk of falls, fractures and consequent hospitalisation. There is a growing body of evidence to support the effectiveness of exercise in addressing the adverse effects of advanced PCa treatment (Hayes et al., 2019). Despite recommendations for men with bone metastases to participate in supervised exercise, there is often a reticence on the part of clinicians and/or patients due to concerns of fragility fracture or other adverse effects (Hart et al., 2017). These men with significant treatment toxicity and a high disease burden are an important patient group for whom exercise has been demonstrated to improve quality of life (QoL) (Galvão et al., 2018). To inform policy and improve accessibility of exercise for advanced PCa patients, it is important to determine whether such interventions represent value for money.
DOI
10.1111/ecc.13479
Related Publications
Edmunds, K. (2021). Cost-effectiveness of exercise medicine for prostate cancer. https://ro.ecu.edu.au/theses/2405
Access Rights
subscription content
Comments
Edmunds, K., Scuffham, P., Reeves, P., Galvão, D. A., Taaffe, D. R., Newton, R. U., . . . Tuffaha, H. (2021). Demonstrating the value of early economic evaluation alongside clinical trials: Exercise medicine for men with metastatic prostate cancer. European Journal of Cancer Care, 30(5), Article e13479.
https://doi.org/10.1111/ecc.13479